Ophthalmic preparation and application thereof in retarding myopia progress

Abstract

The invention provides an ophthalmic preparation and application thereof in slowing down myopia progression, the ophthalmic preparation is brimonidine, and it is found and proved for the first time that intravitreal injection of brimonidine can delay growth of an ocular axis so as to effectively slow down the myopia progression. Due to the fact that brimonidine is injected into the vitreous cavity, growth of an ocular axis can be delayed, and the diopter of eyeballs is improved. Meanwhile, under the action of the medicine, the intraocular pressure is also remarkably reduced. The ophthalmic preparation can effectively slow down the progression of myopia, has a potential effect of delaying the progression of the aging eye course, and has a very good clinical application prospect.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, in particular to an ophthalmic preparation and application thereof in slowing down the progression of myopia. Background Art

[0002] Myopia is a common public health problem that is not fully recognized, with huge potential economic impact and far-reaching consequences. Anatomically, myopia is mainly caused by excessive growth of the axial length. When myopia develops to >-6.0D or the axial length is ≥26.0 or 26.5mm, it is called high myopia. Among patients with high myopia, some are pathological myopia patients. The most common morphological change of the eyeball is posterior scleral staphyloma, which is also one of the key points that distinguish pathological myopia from general high myopia. In most cases, posterior scleral staphyloma will lead to other complications, such as atrophy, traction or neovascular maculopathy, while general high myopia will also lead to retinal detachment, cataracts and increased risk of glaucoma.

[0003] At present, the three major measures for the prevention and control of myopia in children that have been widely recognized in clinical practice are: sufficient outdoor activities, low-concentration atropine eye drops and orthokeratology lenses. More and more studies have shown that ensuring 2 hours of outdoor activities every day can effectively prevent the occurrence of myopia in children. The "outdoor activities" described here do not mean guiding children to do sports in an outdoor environment, but to stay in an outdoor environment, even to read in an outdoor environment. This is because the light intensity outdoors is significantly higher than the light intensity indoors, and is hundreds of times that of indoors. However, it should be noted that outdoor activities are only effective for children who have not yet developed myopia, and have very limited effects on children who have already developed myopia. In recent years, a large number of studies have shown that 0.01% low-concentration atropine eye drops are effective in slowing the progression of myopia in children, but the side effects caused by them, such as photophobia, difficulty in near vision, and dry mouth, limit their widespread clinical application. Orthokeratology lenses have a clear control effect on the progression of myopia in children, but their expensive price, regular follow-up, regular re-examination and complex lens maintenance procedures make them difficult to popularize. Therefore, exploring new methods for the prevention and control of myopia remains a focus in this field.

[0004] Clinical studies have shown that the use of low-concentration atropine eye drops once a night can effectively slow the progression of human myopia. It is generally believed that atropine prevents the development of myopia by interacting with muscarinic acetylcholine receptors. Atropine is a non-selective muscarinic receptor antagonist. In the human eye, the parasympathetic nerves can control physiological functions such as pupil, accommodation and vasoconstriction. At present, dopamine and acetylcholine are considered to be two molecules closely related to the growth and development of the eye. The reduction of dopamine release is considered to be an important change in the occurrence and development of myopia. Atropine is an acetylcholinergic receptor antagonist. The control effect of atropine eye drops on myopia suggests that the cholinergic signaling pathway plays an important role in the regulation of myopia. However, in clinical practice, atropine eye drops are only used in a small range for myopia prevention and control. The main reason is that atropine eye drops will bring other inevitable side effects while controlling myopia, such as dilated pupils, photophobia, dry mouth, red skin and increased heart rate. All these limit the clinical application of atropine. Therefore, more specific drugs for preventing and controlling myopia still need to be developed.

[0005] Orthokeratology (OK) is a special hard contact lens, which is mainly used to correct myopia and astigmatism. It has the advantages of non-surgical correction, nighttime wear, slowing the development of myopia and comfort. It can effectively correct vision without surgery, suitable for patients who do not want to undergo surgery, and can be worn while sleeping. After waking up during the day, there is no need to wear glasses or contact lenses, which is convenient for daily life. However, orthokeratology also has some disadvantages, such as high price; an adaptation period may be required when wearing it for the first time, and some users may feel discomfort or vision fluctuations; at the same time, the maintenance requirements are high, and strict cleaning and care are required to prevent eye infections and other complications. In addition, not everyone is suitable for using orthokeratology, and some patients may not be able to obtain the ideal vision correction effect. Long-term wear may also cause corneal deformation or other eye problems, so regular review is required. Due to the above shortcomings, orthokeratology is difficult to popularize.

[0006] In short, the three major measures for myopia prevention and control that have been widely recognized in clinical practice are: outdoor activities, low-concentration atropine eye drops and orthokeratology lenses. However, in the context of my country's emphasis on education, it is difficult for students to persist in 2 hours of outdoor activities every day. Low-concentration atropine eye drops have many side effects, and myopia rebounds significantly after discontinuation of the drug. Orthokeratology lenses are expensive, and the lens care process is complicated, making them difficult to popularize. Therefore, seeking new methods for myopia prevention and control remains the focus of this field. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide an ophthalmic preparation and its application in slowing down the progression of myopia. The ophthalmic preparation is brimonidine, which can delay the growth trend of the eye axis, slow down the increase of myopic diopter, and thus slow down the progression of myopia.

[0008] In order to solve the above problems, the present invention provides an ophthalmic preparation and its use in slowing down the progression of myopia, wherein the ophthalmic preparation is brimonidine.

[0009] According to an ophthalmic preparation provided by the present invention and its use in slowing down the progression of myopia, 130 healthy male colored guinea pigs aged 3 weeks were selected, and the right eyes of the guinea pigs in the experimental group were worn with diffuse lenses for monocular myopia modeling to verify the effectiveness of brimonidine in slowing down the progression of myopia.

[0010] According to an ophthalmic preparation provided by the present invention and use thereof in slowing down the progression of myopia, a guinea pig myopia model was established by wearing a diffusion lens in the right eye of the guinea pig.

[0011] According to an ophthalmic preparation provided by the present invention and its use in slowing the progression of myopia, 16 3-week-old male spotted guinea pigs were selected as experimental subjects, and the eye growth, refractive development and changes in intraocular pressure of the guinea pigs in the monocular myopia modeling group were observed under indoor lighting conditions to determine whether the experimental modeling was successful, provide basic data for subsequent research on the use of drugs to intervene in the progression of myopia, and provide experimental basis for further clarifying the pathogenesis of myopia and seeking reasonable prevention and control measures.

[0012] According to an ophthalmic preparation provided by the present invention and use thereof in slowing down the progression of myopia, the control eye vs. myopia model eye: the refractive power on the 20th day was 0.97±0.18D vs. -0.13±0.38D, F=6.921, P=0.02.

[0013] According to an ophthalmic preparation provided by the present invention and use thereof in slowing down the progression of myopia, the difference in axial length between control eyes and myopic model eyes on day 0 and day 21 was 0.29±0.04 mm and 0.45±0.03 mm, F=11.655, P=0.004).

[0014] According to an ophthalmic preparation provided by the present invention and its use in slowing down the progression of myopia, 48 3-week-old male spotted guinea pigs were selected as experimental subjects to provide an experimental basis for seeking a reasonable administration method of brimonidine for inhibiting myopia.

[0015] According to an ophthalmic preparation provided by the present invention and its use in slowing down the progression of myopia, three different administration methods, namely local eye drops, subconjunctival injection and intravitreal injection, were selected to observe the effects of local eye drops, subconjunctival injection and intravitreal injection of brimonidine in inhibiting the progression of experimental myopia in guinea pigs, so as to explore the most effective administration method of brimonidine in slowing down the progression of myopia.

[0016] According to an ophthalmic preparation provided by the present invention and its use in slowing down the progression of myopia, 30 3-week-old male spotted guinea pigs were selected as experimental subjects to observe the effects of intravitreal injection of brimonidine at different concentrations in slowing down the progression of myopia in guinea pigs.

[0017] According to an ophthalmic preparation provided by the present invention and use thereof in slowing down the progression of myopia, 4 different concentrations of brimonidine, 2 μg / μL, 4 μg / μL, 20 μg / μL and 40 μg / μL, are selected for intravitreal injection.

[0018] According to an ophthalmic preparation and use thereof in slowing down myopia progression provided by the present invention, the different concentrations of brimonidine are used to explore the most effective administration concentration for slowing down myopia progression in guinea pigs.

[0019] According to an ophthalmic preparation provided by the present invention and its use in slowing down the progression of myopia, 36 3-week-old male spotted guinea pigs were selected as experimental subjects, and under the lighting conditions of the observation room, the effects of intravitreal injection of 4 μg / μL brimonidine on the eye growth and refractive development of the guinea pigs in the monocular myopia modeling group were observed, and the changes in the intraocular pressure of the guinea pigs were observed to explore the effect of intravitreal injection of brimonidine on the onset of myopia and the relationship between intraocular pressure and the occurrence and development of myopia, so as to provide an experimental basis for further clarifying the pathogenesis of myopia and seeking reasonable prevention and control measures.

[0020] According to an ophthalmic preparation provided by the present invention and its use in slowing down the progression of myopia, each batch of experiments lasts for 21 days, using a rebound tonometer to measure intraocular pressure, static retinal shadows to measure refraction, and an A-type ultrasonic biometer to detect axial length.

[0021] The beneficial effects of the present invention are as follows: the ophthalmic preparation of the present invention and its application in slowing down the progression of myopia, in order to achieve the purpose of delaying the growth trend of the eye axis, slowing down the increase of myopic diopter, and thus slowing down the progression of myopia, a guinea pig myopia model is established by wearing a diffusion lens in the right eye of the guinea pig (control eye vs myopic modeling eye: diopter on the 20th day, 0.97±0.18D vs -0.13±0.38D, F=6.921, P=0.02; eye axis difference between the 0th day and the 21st day, 0.29±0.04mm and 0.45±0.03mm, F=11.655, P=0.004). Among the three different administration methods of local eye drops, subconjunctival injection and intravitreal injection, it is determined that intravitreal injection of brimonidine can most effectively slow down the progression of myopia. Among the four intravitreal injection concentrations of 2μg / μL, 4μg / μL, 20μg / μL and 40μg / μL, it was determined that the most effective concentration of brimonidine for slowing the progression of myopia in guinea pigs was 4μg / μL. The axial length, refractive power and intraocular pressure of the intravitreal injection of brimonidine group, the intravitreal injection of sterile water and the non-injected control group were measured, and the statistical differences were calculated. It can be seen from the above technical solution that compared with the prior art, the present invention discloses an ophthalmic preparation that is simple, easy to prepare and has good stability. It is used in the form of a liquid medicine for preparation and can be used for local eye drops, subconjunctival injections and intravitreal injections. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The specific embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings, wherein:

[0023] Figure 1 The guinea pig monocular myopia model provided by the present invention;

[0024] Figure 2 Changes in intraocular pressure of the myopia modeling group and the control group provided by the present invention;

[0025] Figure 3 The intraocular pressure changes of brimonidine injected into the vitreous cavity provided by the present invention. DETAILED DESCRIPTION

[0026] Example 1 Construction of monocular myopia guinea pig model

[0027] 1. Experimental methods

[0028] (1) Sixteen three-week-old male guinea pigs were selected as experimental subjects to observe the eye growth, refractive development and changes in intraocular pressure of the guinea pigs in the monocular myopia model group under indoor lighting conditions, explore the effect of diffuse light lenses on the onset of myopia, and clarify whether the experimental model is successful. This will provide basic data for subsequent studies on the use of drugs to intervene in the progression of myopia and provide experimental basis for further clarifying the pathogenesis of myopia and seeking reasonable prevention and control measures.

[0029] (2) After 3 days of adaptive feeding and quarantine, the guinea pigs began the experiment, which lasted for 21 days. During the experiment, the light cycle was 12:12h, the lighting time was 8:00-20:00, and the electronic switch was uniformly controlled. The indoor artificial lighting source was an LED flat panel lamp (FRS-60W, color temperature 5836K, brightness 3134cd / m2), continuous spectrum, and the main peaks of the output spectrum were located at 453nm and 545nm respectively. The light intensity of the plane connecting the guinea pig's eyes was measured by an illuminance meter (TES-1332A illuminance meter, Taiwan TES Company) to be 150-200lux.

[0030] (3) A-type ultrasound examination of the eyeballs of guinea pigs was performed before modeling, on the 7th day, 14th day and 21st day after modeling. Static retinoscopy was performed before modeling, on the 10th day and 20th day after modeling. Intraocular pressure was measured before modeling, on the 1st day, 3rd day, 5th day, 7th day, 9th day, 11th day, 13th day, 15th day, 17th day, 19th day and 21st day after modeling. All operations were performed by the same skilled examiner who was unaware of the experimental design and grouping.

[0031] (4) The axial length, refractive power and intraocular pressure of the experimental group and the control group were measured. The measurement results are shown in Tables 1-2 and Figure 2 shown.

[0032] Table 1 Changes in the difference in axial length between the myopia modeling group and the control group (mm)

[0033]

[0034] Table 2 Changes in refraction between myopia modeling group and control group (D)

[0035]

[0036] 2. Experimental results

[0037] The axial length of the eyes in the myopia modeling group was significantly longer than that of the control eyes, and the refractive power drifted significantly toward myopia compared with the control eyes, and both were statistically significant. During the 21-day experimental period, the intraocular pressure of the myopia modeling eyes was significantly higher than that of the control eyes, and it was statistically significant. Under 21 days of negative lens induction, the intraocular pressure of the lens-induced eyes gradually increased compared with the control eyes. Compared with the control eyes, on the 21st day of the experiment, the intraocular pressure of the lens-induced eyes increased by 7.92±1.43mmHg, and a significant statistical difference appeared on the 21st day (P<0.0001), but there was no statistical difference at the beginning of the experiment (P=0.27).

[0038] Example 2 Exploring the administration method of brimonidine to slow down the progression of myopia

[0039] 1. Experimental methods

[0040] (1) 48 3-week-old male spotted guinea pigs were selected as experimental subjects, and the obtained data were compared with the relevant data of the myopia model eyes in Example 1 to observe the effects of brimonidine topical eye drops, subconjunctival injections, and intravitreal injections in inhibiting the progression of myopia in guinea pigs. A reasonable administration method of brimonidine for inhibiting myopia was sought.

[0041] (2) The eyes of 48 guinea pigs were observed under slit lamp. After confirming that they had no eye diseases, they were randomly divided into 6 groups: brimonidine eye drop group, sterile water eye drop group, brimonidine subconjunctival injection group, sterile water subconjunctival injection group, brimonidine intravitreal injection group, and sterile water intravitreal injection group, with 8 animals in each group. The data obtained were compared with the data of the myopia model group in Chapter 1. The brimonidine concentration used in the brimonidine eye drop group, brimonidine subconjunctival injection group, and brimonidine intravitreal injection group was 4μg / μL. The amount of each eye drop, subconjunctival injection, and intravitreal injection was 5μL. The right eyes of the 48 animals were all equipped with diffuse lenses according to the experimental method described in Chapter 1, and they were myopia model eyes. Starting from day 0, during the 21-day experimental period, the brimonidine and sterile water eye drop groups were injected twice a day, and the injection group was injected once every 4 days with 5μL of freshly prepared solution. Starting from day 0, axial length was measured by ocular A-ultrasound every 7 days, and refraction was measured by static retinoscopy every 10 days for a total of 21 days.

[0042] (3) The experimental environment (including lighting conditions) is the same as that in Example 1.

[0043] (4) A-type ultrasound examination was performed on the guinea pigs' eyes before modeling, and on the 7th, 14th, and 21st days after modeling. Static retinoscopy was performed on the guinea pigs' eyes before modeling, and on the 10th and 20th days after modeling. The examiners were unaware of the experimental design and grouping.

[0044] (5) The axial length, refractive power and intraocular pressure of the experimental group and the control group were measured. The measurement results are shown in Table 3-8.

[0045] Table 3 Changes in axial length of the subconjunctival injection group and myopia modeling group (mm)

[0046]

[0047] Table 4 Changes in refraction between the subconjunctival injection group and the myopia modeling group

[0048]

[0049] Table 5 Changes in axial length of the local eye drops group and the myopia modeling group (mm)

[0050]

[0051] Table 6 Changes in refractive power (D) of the local eye drops group and the myopia modeling group

[0052]

[0053] Table 7 Changes in axial length of the vitreous cavity injection group and myopia modeling group (mm)

[0054]

[0055] Table 8 Refractive power changes (D) in the intravitreal injection group and the myopia modeling group

[0056]

[0057] 2. Experimental results

[0058] The results of the study indicate that not all drug delivery methods can work in slowing the progression of myopia. Intravitreal injection of brimonidine can slow the progression of myopia, while topical eye drops and subconjunctival injections cannot.

[0059] Example 3 Exploring the efficacy of different concentrations of brimonidine intravitreal injection in slowing down the progression of myopia in guinea pigs

[0060] 1. Experimental methods

[0061] (1) Thirty 3-week-old male guinea pigs were selected as experimental subjects. The effect of intravitreal injection of brimonidine at different concentrations on slowing down the progression of myopia in guinea pigs was observed, and the reasonable dosage concentration was sought.

[0062] (2) Thirty 3-week-old healthy male guinea pigs were randomly divided into 5 groups: modeling only, 2 μg / μL, 4 μg / μL, 20 μg / μL, and 40 μg / μL, with 6 animals in each group.

[0063] (3) The right eyes of all 30 animals were fitted with diffuse lenses according to the experimental method described in Chapter 1. Every 4 days, 5 μL of the prepared solution was injected into the vitreous cavity of the right eye of the guinea pig, and the axial length and refractive power were measured every 10 days for a total of 21 days.

[0064] (4) The experimental environment (including lighting conditions) is the same as that in Example 1.

[0065] (5) The axial length and refractive power of the experimental group and the control group were measured. The measurement results are shown in Tables 9-10.

[0066] Table 9 Changes in diopter difference after intravitreal injection of different concentrations of brimonidine (D)

[0067]

[0068] Table 10 Changes in axial length after intravitreal injection of different concentrations of brimonidine

[0069]

[0070] 2. Experimental results

[0071] The effects of 4 different concentrations of brimonidine intravitreal injection on myopia progression in guinea pigs were compared with the model eye alone. The results showed that 4 μg / μL could effectively slow down the progression of myopia in guinea pigs, while other concentrations were ineffective.

[0072] Example 4 Exploring the efficacy of different concentrations of brimonidine intravitreal injection in slowing down the progression of myopia in guinea pigs

[0073] 1. Experimental methods

[0074] (1) Thirty-six 3-week-old male guinea pigs were selected as experimental subjects to observe the effects of intravitreal injection of 4 μg / μL brimonidine on the growth and refractive development of the eyeball of monocular myopia model guinea pigs under indoor lighting conditions. The changes in intraocular pressure of the guinea pigs were also observed to explore the effect of intravitreal injection of brimonidine on the onset of myopia, the relationship between intraocular pressure and the occurrence and development of myopia, and to further clarify the pathogenesis of myopia and seek reasonable prevention and control measures.

[0075] (2) Thirty-six 3-week-old healthy male guinea pigs were randomly divided into three groups: a brimonidine intravitreal injection group and a sterile water intravitreal injection group, with 12 pigs in each group (n=12 in each group).

[0076] (3) The right eyes of the 36 animals were fitted with diffuse lenses according to the experimental method described in Chapter 1. Starting from day 0, 5 μL of freshly prepared brimonidine solution was injected into the vitreous cavity of the right eye of the guinea pig every 4 days, the axial length and refraction were measured every 7 days, and the intraocular pressure was measured every 2 days for a total of 21 days.

[0077] (4) The experimental environment (including lighting conditions) is the same as that in Example 1.

[0078] (5) Static retinoscopy and A-type retinoscopy were performed on the guinea pigs before modeling and on the 7th, 14th and 21st days after modeling.

[0079] Ultrasonic examination. The intraocular pressure of guinea pigs was measured with a rebound tonometer before modeling and on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th and 21st day after modeling. The examiners were blinded to the experimental design and grouping.

[0080] (6) The axial length, refractive power and intraocular pressure of the experimental group and the control group were measured. The measurement results are shown in Tables 11-12 and Figure 3 shown.

[0081] Table 11 Effect of intravitreal brimonidine injection in slowing down axial length growth (mm)

[0082]

[0083] Repeated measures ANOVA, *main effect, #interaction effect, @myopia modeling group+intravitreal injection of brimonidine, & myopia modeling group+intravitreal injection of sterile water.

[0084] Table 12 Changes in refraction after intravitreal injection of brimonidine (D)

[0085]

[0086] @Myopia modeling group + intravitreal injection of brimonidine, &Myopia modeling group + intravitreal injection of sterile water.

[0087] 2. Experimental results

[0088] This part of the experiment proved that brimonidine can slow down the progression of myopia. By measuring and recording the changes in axial length, refraction and intraocular pressure during the 21-day experimental period, the results of this part of the study showed that compared with the two groups of modeling only and intravitreal injection of sterile water, intravitreal injection of 4μg / μL brimonidine can slow down the progression of form deprivation myopia in guinea pigs.

[0089] In summary, among the three different administration methods of topical eye drops, subconjunctival injection and intravitreal injection, intravitreal injection of brimonidine can most effectively slow down the progression of myopia in guinea pigs. Intravitreal injection of 4μg / μL brimonidine can significantly reduce the progression of myopia in guinea pigs.

[0090] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

[0091] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge scope of ordinary technicians in this field without departing from the purpose of the present invention.

Claims

1. An ophthalmic preparation and its use in slowing down the progression of myopia, characterized in that: The ophthalmic preparation is brimonidine.

2. An ophthalmic preparation according to claim 1 and its use in slowing down the progression of myopia, characterized in that: A total of 130 healthy male pigmented guinea pigs aged 3 weeks were selected. The right eyes of the experimental group of guinea pigs were fitted with diffuse lenses for monocular myopia modeling to verify the effectiveness of brimonidine in slowing down the progression of myopia.

3. The use according to claim 2, characterized in that: The guinea pig myopia model was established by wearing a diffusion lens in the right eye of the guinea pig.

4. The use according to claim 2, characterized in that: Sixteen three-week-old male guinea pigs were selected as experimental subjects. The eye growth, refractive development and changes in intraocular pressure of the guinea pigs in the monocular myopia modeling group were observed under indoor lighting conditions to determine whether the experimental modeling was successful. This provided basic data for subsequent research on the use of drugs to intervene in the progression of myopia and provided experimental basis for further clarifying the pathogenesis of myopia and seeking reasonable prevention and control measures.

5. The use according to claim 4, characterized in that: Control eyes vs myopic model eyes: refraction on the 20th day, 0.97±0.18D vs -0.13±0.38D, F=6.921, P=0.

02.

6. The use according to claim 4, characterized in that: Control eyes vs. myopic model eyes: the difference in axial length between day 0 and day 21 was 0.29±0.04 mm and 0.45±0.03 mm, F=11.655, P=0.004).

7. The use according to claim 2, characterized in that: Forty-eight 3-week-old male guinea pigs were selected as experimental subjects to provide experimental basis for seeking a reasonable administration method of brimonidine to inhibit myopia.

8. The use according to claim 7, characterized in that: Three different administration methods, namely local eye drops, subconjunctival injection and intravitreal injection, were selected to observe the effects of brimonidine in inhibiting the progression of experimental myopia in guinea pigs, so as to explore the most effective administration method of brimonidine in slowing the progression of myopia.

9. The use according to claim 2, characterized in that: Thirty 3-week-old male guinea pigs were selected as experimental subjects to observe the effect of intravitreal injection of different concentrations of brimonidine in slowing down the progression of myopia in guinea pigs.

10. The use according to claim 9, characterized in that: Four different concentrations of brimonidine, 2μg / μL, 4μg / μL, 20μg / μL and 40μg / μL, were selected for intravitreal injection.

11. The use according to claim 10, characterized in that: The different concentrations of brimonidine are used to explore the most effective administration concentration for slowing down the progression of myopia in guinea pigs.

12. The use according to claim 2, characterized in that: Thirty-six 3-week-old male guinea pigs were selected as experimental subjects. Under indoor lighting conditions, the effects of intravitreal injection of 4 μg / μL brimonidine on the eye growth and refractive development of guinea pigs in the monocular myopia model group were observed. The changes in intraocular pressure of the guinea pigs were observed to explore the effect of intravitreal injection of brimonidine on the onset of myopia and the relationship between intraocular pressure and the occurrence and development of myopia, so as to provide an experimental basis for further clarifying the pathogenesis of myopia and seeking reasonable prevention and control measures.

13. The use according to claims 4, 7, 9 and 12, characterized in that: Each experiment lasted for 21 days. IOP was measured using a rebound tonometer, refraction was measured using a static retinoscopy, and axial length was measured using an A-type ultrasonic biometer.

Images